S581 A Community-Based Study to Assess a Prognostic Assay's Impact on Gastroenterologists' Barrett's Esophagus Patient Surveillance and Treatment Recommendations

Stacey Gilbert,Daniel Lunz,Sarah Laun,Jerome Braun,Andrew Kalra,Suji Kim,Francia Pierre,Tara Maddala,Stephen J. Meltzer
DOI: https://doi.org/10.14309/01.ajg.0001031692.94189.19
2024-10-26
The American Journal of Gastroenterology
Abstract:Esopredict is an epigenetic assay that uses DNA methylation to identify early signals of neoplastic progression by stratifying patients with non-dysplastic (NDBE), indefinite-for-dysplasia (IND), or low-grade dysplasia (LGD) Barrett's esophagus (BE) who may be at risk of developing high grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) within 5 years. The purpose of this single arm prospective study is to determine whether Esopredict results influence gastroenterologists' changes to BE treatment and/or surveillance recommendations.
gastroenterology & hepatology
What problem does this paper attempt to address?